Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools GIST

GIST

Programs, trials, and reported response and survival for gastrointestinal stromal tumor.

Data as of 11.07.2026

All studies

Velzatinib (IDRX-42, GSK6042981)

StrateGIST 1

GSK · Phase 1 · Active, not recruiting · Enrollment 276

NCT05489237

Catalyst Primary completion. 03.10.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
Velzatinib 300 mg tablet (or 400 mg capsule), 2Ln/r
Velzatinib, 1Ln/r

A count stays a count. This page does not turn a count into a percent.